Covered recipient · General Payments record
RESHMA C KATIRA
Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist
General Payments · PY2018–2024
$1,457.71
- Reported across 54 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $393.68 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $98.39 | 3 |
| ABBVIE INC. | $70.14 | 4 |
| Amgen Inc. | $64.94 | 3 |
| Genentech USA, Inc. | $43.58 | 2 |
| Regeneron Healthcare Solutions, Inc. | $37.47 | 1 |
| Tarsus Pharmaceuticals, Inc. | $36.83 | 1 |
| Bausch & Lomb Americas Inc. | $23.84 | 1 |
| Rhythm Pharmaceuticals, Inc. | $18.49 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.62 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104038696 | CMS |
| ABBVIE INC. | $15.15 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104038698 | CMS |
| ABBVIE INC. | $16.65 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104038700 | CMS |
| ABBVIE INC. | $13.72 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104038702 | CMS |
| Amgen Inc. | $21.54 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115791596 | CMS |
| Amgen Inc. | $22.36 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115791605 | CMS |
| Amgen Inc. | $21.04 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115791612 | CMS |
| Astellas Pharma US Inc | $34.13 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139334582 | CMS |
| Astellas Pharma US Inc | $31.99 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139401553 | CMS |
| Astellas Pharma US Inc | $32.27 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139442680 | CMS |
| Bausch & Lomb Americas Inc. | $23.84 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140432786 | CMS |
| Genentech USA, Inc. | $27.75 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133095430 | CMS |
| Genentech USA, Inc. | $15.83 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133095426 | CMS |
| Regeneron Healthcare Solutions, Inc. | $37.47 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114082971 | CMS |
| Rhythm Pharmaceuticals, Inc. | $18.49 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141480622 | CMS |
| Tarsus Pharmaceuticals, Inc. | $36.83 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139107033 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.